iAnthus Capital Holdings Inc.

iAnthus Capital launches second New York cannabis dispensary

The dispensary is called Citiva Hudson Valley and is located in Wappingers Falls, New York

dispensary sign
Only registered patients with a New York medical cannabis card may purchase cannabis products in the state

iAnthus Capital Holdings (CSE:IAN) (OTCQX:ITHUF) announced Wednesday that it has opened its second New York cannabis dispensary in the Dutchess County town of Wappingers Falls.

The 2,600 square foot dispensary is called Citiva Hudson Valley and is located at 1147 Route 9, about 90 minutes north of New York City.

On the list of offerings at the new dispensary are vape cartridges, tinctures, capsules and powders.

READ: iAnthus Capital Holdings' revenue climbs in first half of 2018, but sees a net loss of US$36.2mln

The opening of a Hudson Valley location follows iAnthus’s move to launch its first New York dispensary in Brooklyn in December 2019. Two additional locations in Staten Island and Chemung County are in the works.

"The opening of our Citiva Hudson Valley dispensary is a major milestone for iAnthus, as it marks the 20th dispensary opened by the Company," said Hadley Ford, CEO of iAnthus. "2019 will be full of catalysts and exciting developments for Citiva, including the much-anticipated completion of our cultivation facility in Warwick, New York, and the opening of dispensaries in Staten Island and Chemung County."

READ: Cannabis group iAnthus unveils $835m takeover of MPX Bioceutical

IAnthus operates 20 dispensaries in 11 US states. Only registered patients with a New York medical cannabis card may purchase cannabis products.

The cannabis company's shares finished 1.9% lower to hit C$7.15 on Tuesday.

Contact Ellen Kelleher at [email protected]

Quick facts: iAnthus Capital Holdings Inc.

Price: $2.75

Market: CSE
Market Cap: $429.1 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Qrons seeking to find a cure for traumatic brain injuries...

Qrons Inc (OTCQB: QRON) CEO Jonah Meer tells Proactive the New York-based biotechnology company is developing two products, one of which involves a 3D-printable scaffold, aimed at helping to treat traumatic brain injuries. Meer says that traumatic brain injuries are the number one cause of...

7 hours, 11 minutes ago

2 min read